Northpond, Octopus lead $30m series-A for Ori Biotech

Northpond is a US-based life sciences investor, while Octopus invests from a series of VCTs and institutional funds.

Existing investors Amadeus Capital Partners, Delin Ventures and Kindred Capital also joined the round.

The fresh capital will be used to bring Ori's product to market.

Previous funding
Ori Biotech raised £7m from an investor syndicate comprising Amadeus Capital Partners, Delin Ventures, Kindred Capital and a London-based family office, alongside a group of angel investors in January 2020.

Company
Ori's platform was designed to address the requirements of a new generation of personalised cell and gene therapies (CGT). By automating and standardising CGT manufacturing in a closed platform, Ori offers developers of therapeutics the opportunity to scale from pre-clinical process development to commercial-scale manufacturing. It is based in London and was founded in 2015.

People
Ori Biotech – Jason Foster (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• healthcare
• Octopus Ventures
• Amadeus Capital